ReWalk Robotics Q1 revenue up 40% to $1.2M; gross margin improves to 46.4%

Lifeward Ltd.

2023-Q1 EPS reported -$0.07 revenue$1,230,000

Total revenue $1.2M vs $0.9M in Q1 2022, a 40% increase driven by higher US unit sales.
Gross margin 46.4% vs 30.3% in Q1 2022, up 16 percentage points on higher volumes and ASP.
Net loss $4.3M vs $4.4M; non-GAAP net loss $4.0M vs $4.1M; cash $61.9M with no debt.
FDA 510(k) clearance for ReWalk Personal Exoskeleton on stairs and curbs in March 2023.
First Medicare claim submitted; ten additional submissions planned in Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lifeward Ltd. reported the three months ended March 31, 2023 results: revenue $1.2 million, net income $4.3 million.

Period: the three months ended March 31, 2023
Revenue: $1.2 million
Net income: $4.3 million
Result: reported results

Exact text from the filing

announced its financial results for the three months ended March 31, 2023. Highlights of the first quarter of 2023 include: • Total revenue for the first quarter of 2023 was $1.2 million, as compared to $0.9 million in the first quarter of 2022, up 40%; • Gross margin was 46.4% in Q1’23, as compared to 30.3% in Q1’22, a 16 percentage point increase; • Operating

View on SEC.gov

47 earnings releases filed in the last 30 days. Browse all earnings releases →

Lifeward Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-23-001822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.